Currently, there are two anti-HIV drugs targeting the entry process: while maraviroc binds to the coreceptor CCR5 thus being used to treat infections by CCR5-tropic HIV isolates, the peptide drug enfuvirtide (T-20) acts by blocking the fusion between viral and cell membranes [2–4]. This evidence concerns the gene CCR5 and infection.